Matthew Shinkle is an Online Content Editor for Healio, a medical news website. He covers a wide range of topics in the field of medicine, including research studies, treatment advancements, and disparities in healthcare. His work has also been featured in the Haddonfield Sun.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Matthew Shinkle's coverage predominantly revolves around healthcare and pharmaceuticals, focusing on scientific research and data-driven insights. Given the emphasis on citing data, pitches to him should provide robust scientific evidence or studies that uncover significant advancements or disparities in cancer treatment. Additionally, given his focus on racial disparities and drug therapy, he may be interested in stories concerning innovative approaches to addressing these issues.
Sources with a deep understanding of clinical trials and medical research could effectively engage Matthew through providing valuable context for new therapies, especially those related to breast cancer, lymphoma, or drugs targeting specific patient populations.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Mindy Valcarcel, Matthew Shinkle
Gastric Cancer Awareness Month, observed every November, is intended to educate the public about the potential causes and risk factors for the disease.
By: Mindy Valcarcel, Matthew Shinkle
Treatment with immune checkpoint inhibitors appeared linked with higher risk for venous thromboembolism among adults with metastatic lung cancer, according to study results presented at CHEST Annual Meeting.
By: Mindy Valcarcel, Matthew Shinkle
Key takeaways: Physician assistant/associate programs grew considerably from 2013 to 2021.
By: Matthew Shinkle, Mindy Valcarcel
SAN DIEGO — Treatment with axicabtagene ciloleucel conferred durable benefit to patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, according to study results presented at ASH Annual Meeting and Exposition.
By: Matthew Shinkle, Mark Leiser
SAN ANTONIO — The addition of pyrotinib to first-line trastuzumab and docetaxel improved PFS among patients with HER2-positive metastatic breast
By: Matthew Shinkle, Mindy Valcarcel, Josh Friedman
SAN ANTONIO — The novel antibody-drug conjugate SHR-A1811 exhibited promising antitumor activity as neoadjuvant treatment for patients with
By: Matthew Shinkle, Mindy Valcarcel, Josh Friedman
SAN ANTONIO — Surgical axillary staging as part of breast-conserving therapy may not be necessary for certain patients with early invasive breast cancer, according to findings presented at San Antonio Breast Cancer Symposium.
By: Josh Friedman, Mark Leiser, Matthew Shinkle
SAN ANTONIO — Elevated BMI increased risk for breast cancer mortality and distant recurrence among women with early-stage disease, according to findings presented at San Antonio Breast Cancer Symposium.
The FDA approved ensartinib for the treatment of certain patients with ALK-positive locally advanced or metastatic non-small cell lung cancer.The indication applies to use of the agent for adults not previously prescribed an ALK inhibitor.
By: Matthew Shinkle, Mindy Valcarcel
SAN DIEGO — Tabelecleucel provided durable benefit to solid organ or allogeneic hematopoietic cell transplant recipients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease, according to study results.
(833) 317-6278 
